NobelReplace/Replace Select Tapered line extension

10 June 2010, 10:38 CET

Nobel Biocare has extended its NobelReplace and Replace Select Tapered implant lines to provide users with more flexibility.

The standardized drilling protocol, complete color coding and tri-channel connection that offer exceptional ease of use are only a few of the features that have made NobelReplace/Replace Select Tapered the world’s most used implant system. And now, we're making it even better!

Here are some of the improvements to the NobelReplace/Replace Select Tapered implant family:

  • Available now are new implant lengths of 11.5 mm for both implant lines, while 8 mm implants have been added to the Replace Select system for consistency.
  • A new plate has been developed for the surgical kit. This features a new layout that better identifies and supports the surgical workflow and also clearly displays the drill protocol. Of course this new plate accommodates the new 11.5 mm drills and will be automatically shipped along with a first purchase of any 11.5 mm implant.
  • Impression copings have been made radio-opaque for visibility on x-ray images. 

NobelReplace/Replace Select Tapered line extension

Should you have any questions regarding the new products, please do not hesitate to contact your sales representative or Nobel Biocare customer service.

Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician™ and NobelGuide®) and biomaterials (Creos™). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland, currently employs approximately 2,500 employees worldwide and recorded revenue of EUR 566.8 million in 2013. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the United States. Products and services are available in over 80 countries through subsidiaries and distributors.

This media release contains forward-looking statements based on beliefs of Nobel Biocare’s management. When used in this media release, words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan” and “project” are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.

Media contact

Süha Demokan

Süha Demokan

Vice President Investor & Corporate Relations

Nobel Biocare Management AG 
P.O. Box
CH - 8058 Zurich-Airport

+41 43 211 42 30

+41 79 430 81 46

+41 43 211 58 11

Give us your feedback!

Summarize your comments